Abstract
SELECT is a phase 2 randomized study of P, an investigational PD-1 inhibitor (PD-1i) plus V, an investigational ICOS agonist, vs P in TISvopra selected, immunotherapy naïve, 2nd line non-small cell lung cancer (NSCLC). Tumor inflammation signature (TIS) at and above a designated cut-off, termed TISvopra, was previously associated with improved clinical outcomes in patients treated with V +/- nivolumab. SELECT was designed to demonstrate superiority of P + V vs P in TISvopra selected pts and evaluate 2 doses of V with different pulsatile target engagement (TE) profiles to reduce T cell exhaustion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
